SCHEMBL19419683

SCHEMBL19419683

CN(C)COCc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCCCN4CCCC4)c([N+](=O)[O-])c3)c(Oc3ccccc3)c2)CC1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 9/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19419651 0.93 BCL2 (0.78) BCL2
SCHEMBL1957772 0.90 BCL2 (0.87) BCL2
SCHEMBL1957032 0.90 BCL2 (0.73) BCL2
SCHEMBL1957629 0.87 BCL2 (0.86) BCL2
SCHEMBL1956541 0.86 BCL2 (0.97) BCL2
SCHEMBL1957743 0.86 BCL2 (0.78) BCL2
SCHEMBL1958643 0.86 BCL2 (0.93) BCL2
SCHEMBL1957374 0.85 BCL2 (0.97) BCL2
SCHEMBL1957770 0.85 BCL2 (0.90) BCL2
SCHEMBL1955976 0.84 BCL2 (1.00) BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 BCL2 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback